28

Jan

UPDATED: Merck’s COVID-19 pill effective against Omicron in lab studies

Jan 28 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading…

Read More Here

20

Jan

Dozens of firms to make cheap version of Merck COVID pill for poorer nations

BRUSSELS, Jan 20 (Reuters) - A U.N.-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co's COVID-19 pill molnupiravir for poorer…

Read More Here

09

Dec

Britain starts recruiting for real-world COVID antiviral trial

British researchers started recruitment for a clinical trial to test antiviral COVID-19 treatments for use in people early on in the disease who are at higher risks of complications, starting…

Read More Here

26

Nov

Merck says COVID-19 pill cuts hospitalization, death risk by 30%

Nov 26 (Reuters) - Merck & Co said on Friday updated data from the study of its experimental COVID-19 pill showed lower efficacy in reducing the risk of hospitalization and…

Read More Here

20

Nov

EU advises on Merck COVID pill as reviews rival from Pfizer

The European Union's drug regulator has issued advice on using Merck's COVID-19 pill for adults and began a review of a rival tablet from Pfizer to help member states decide…

Read More Here

04

Nov

UPDATED: Britain approves Merck’s oral COVID-19 pill in world first

Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck and Ridgeback Biotherapeutics, in a boost to…

Read More Here

27

Oct

Merck signs pact to broaden generic manufacturing of COVID-19 pill

WASHINGTON, Oct 27 (Reuters) - Merck & Co has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions…

Read More Here

25

Oct

EU regulator starts real-time review of Merck’s COVID-19 pill

Oct 25 (Reuters) - U.S. drugmaker Merck & Co Inc said on Monday the European Union's drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for…

Read More Here

18

Oct

Merck COVID-19 pill sparks calls for access for lower income countries

Oct 17 (Reuters) - The plan to roll out Merck & Co's promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with…

Read More Here

11

Oct

Merck applies for U.S. emergency authoriaation of COVID-19 pill

Oct 11 (Reuters) - Merck & Co Inc said on Monday it has applied for emergency use authorization in the United States for its oral drug to treat mild-to-moderate patients…

Read More Here

06

Oct

Merck says deal signed with Singapore on COVID-19 antiviral pill

Merck announced on Wednesday a supply and purchase agreement that will provide Singapore with access to its experimental oral COVID-19 antiviral drug, the latest Asian country to try to snap…

Read More Here

01

Oct

Merck’s COVID-19 pill cuts risk of death, hospitalization by 50% in study

Merck & Co Inc's experimental oral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients at risk of severe disease, according to interim…

Read More Here

30

Sep

Merck says research shows its COVID-19 pill works against variants

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta,…

Read More Here

20

Sep

Supply fears lead EU vaccine industry to seek home comforts

European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted…

Read More Here

07

Mar

Merck says study shows COVID-19 drug causes quick reduction in virus

U.S. drugmaker Merck & Co Inc said the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study…

Read More Here

26

Jan

France’s Institut Pasteur stopping one of its potential COVID-19 vaccine projects

France's Pasteur Institute said that it was terminating the development of a Covid-19 vaccine with US pharmaceutical company Merck after clinical trial results proved disappointing. The partners had announced a…

Read More Here

12

Sep

Merck starts recruitment for COVID-19 vaccine trial

U.S. drug maker Merck & Co Inc has begun recruiting participants to its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov. The phase 1/2 trial, which is based…

Read More Here